Novozymes Biopharma is taking another step towards building critical mass within key business areas by moving all its activities in Adelaide, Australia, to Novozymes’ sites in Bagsværd, Denmark and Nottingham, England. This consolidation will streamline the company’s research and development setup within industrial cell culture ingredients and allow for a more focused and cost effective approach to the cell culture ingredients market.

“This is part of the larger strategy of Novozymes BioBusiness where we on an ongoing basis streamline our efforts to ensure focus where we see the most attractive market potentials”, says Thomas Videbæk, Executive Vice President of BioBusiness in Novozymes. “We will continue our market support and strengthen the industrial cell culture group based in Denmark and the UK.”
Unfortunately the reorganization will result in layoffs in Australia. Novozymes will ensure affected employees receive outplacement support and individual severance packages in line with Novozymes’ business ethics.

It is anticipated that the majority of the changes will be completed by the end of 2010.